GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

mirikizumab   Click here for help

GtoPdb Ligand ID: 9846

Synonyms: Antibody I [US9023358] | LY-3074828 | LY3074828 | mirikizumab-mrkz | Omvoh®
Approved drug Immunopharmacology Ligand
mirikizumab is an approved drug (Japan, EMA and FDA (2023))
Compound class: Antibody
Comment: Mirikizumab (LY-3074828) is a humanized monoclonal antibody against human IL-23A (IL-23p19) which is designed for the treatment of autoimmune diseases. It is one of the novel agents for immune-mediated inflammatory diseases discussed in Baker et al. (2018) [1]. The peptide sequences of mirikizumab heavy and light chains are 100% matches to sequences 9 and 10 of Antibody I that is claimed in patent US9023358 [2].
Classification Click here for help
Compound class Antibody
Approved drug? Yes. Japan PMDA (2023)  |  US FDA (2023)  |  EU EMA (2023)
International Nonproprietary Names Click here for help
INN number INN
10657 mirikizumab
Synonyms Click here for help
Antibody I [US9023358] | LY-3074828 | LY3074828 | mirikizumab-mrkz | Omvoh®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 767
Other databases
GtoPdb PubChem SID 363894140
Search PubMed clinical trials mirikizumab
Search PubMed titles mirikizumab
Search PubMed titles/abstracts mirikizumab